



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 April 2026
EMADOC-1700519818-3044024
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Crysvita burosumab

On 23 April 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Crysvita. The marketing authorisation holder for this medicinal product is Kyowa Kirin Holdings B.V.

The CHMP adopted an extension to the existing indication as follows:²

Crysvita is indicated for the treatment of X-linked hypophosphataemia **in infants from 1 month to 1 year of age with hypophosphataemia (see section 5.1)**, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.

Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold

